Cover Image
市場調查報告書

黏多醣症II(MPS II,韓特氏症候群):開發中產品分析

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 251572
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
黏多醣症II(MPS II,韓特氏症候群):開發中產品分析 Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 67 Pages
簡介

韓特氏症或稱黏多醣症II(MPS II),是僅有男性會發病,並會出現影響身體各處症狀的疾病。症狀有爪狀手、舌頭突出、唇、舌、鼻孔肥大等五官變異 、發育遲緩等。治療有骨髓移植,酵素治療及基因治療等。

本報告提供全球各國治療黏多醣症II(MPS II,韓特氏症候群)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

黏多醣症II概要

治療藥的開發

  • 黏多醣症II開發中產品:概要
  • 黏多醣症II開發中產品:比較分析

各企業開發中的黏多醣症II治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 階段不明的產品

黏多醣症II治療藥:開發中的產品一覽(各企業)

黏多醣症II開發治療藥的企業

  • Alexion Pharmaceuticals, Inc.
  • AngioChem Inc.
  • ArmaGen Inc.
  • Bioasis Technologies Inc.
  • Green Cross Corporation
  • Inventiva
  • JCR Pharmaceuticals Co., Ltd.
  • Laboratorios Del Dr. Esteve S.A.
  • RegenxBio Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

黏多醣症II:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

黏多醣症II治療藥:暫停的計劃

黏多醣症II治療藥:中止開發的產品

黏多醣症II相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8198IDB

Summary

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )
  • The report reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics and enlists all their major and minor projects
  • The report assesses Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview
  • Therapeutics Development
    • Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics under Development by Companies
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Products under Development by Companies
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals, Inc.
    • AngioChem Inc.
    • ArmaGen Inc.
    • Bioasis Technologies Inc.
    • Green Cross Corporation
    • Inventiva
    • JCR Pharmaceuticals Co., Ltd.
    • Laboratorios Del Dr. Esteve S.A.
    • RegenxBio Inc.
    • Sangamo BioSciences, Inc.
    • Shire Plc
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGT-182 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EGT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idursulfase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idursulfase beta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JR-032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JR-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTf-I2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTfp-I2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • odiparcil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Pompe, Fabry and Hunter Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGX-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-913 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2016: Preclinical Data from REGENXBIO's RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
      • Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
      • Jul 31, 2015: Bioasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
      • Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital
      • Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire
      • Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial
      • Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome
      • Sep 18, 2014: Bioasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
      • Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome
      • Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria
      • Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182
      • Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
      • Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome
      • Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase
      • Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ArmaGen Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Green Cross Corporation, H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Inventiva, H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Shire Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H1 2016
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top